Business
It’s been a very busy, big and ambitious year for Bioasis Technologies Inc. (TSX-V.BTI, OTC:BIOAF, Forum) – a biopharmaceutical company focused on revolutionizing science by transporting therapeutic payloads across the blood-brain barrier and into the brain. And while much has been accomplished by this cutting-edge biotech in 2020, much more exciting news is expected in the pipeline for 2021. In a relatively short period of time, the Company has generated real shareholder value by developing and commercializing its proprietary brain delivery technology – XB3 – to make life-saving drugs brain-penetrant and deliver those drugs at a therapeutically relevant dose. In this must-hear end-of-year vodcast, Stockhouse Media’s Dave Jackson was joined by CEO Dr. Deborah Rathjen to talk more about the genesis of the amazing xB3 platform, its long-term investment potential, and all things Bioasis moving forward into 2021.